{
    "clinical_study": {
        "@rank": "42053", 
        "arm_group": [
            {
                "arm_group_label": "Herceptin (trastuzumab)", 
                "arm_group_type": "Active Comparator", 
                "description": "Intravenous administration"
            }, 
            {
                "arm_group_label": "SB3 (proposed trastuzumab biosimilar)", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous administration"
            }
        ], 
        "brief_summary": {
            "textblock": "A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the\n      Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab\n      biosimilar) and Herceptin\u00ae in Women with Newly Diagnosed HER2 Positive Early or Locally\n      Advanced Breast Cancer in Neoadjuvant Setting"
        }, 
        "brief_title": "A Study to Compare the Effect of SB3 and Herceptin\u00ae in Women With HER2 Positive Breast Cancer", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "HER2 Positive Early or Locally Advanced Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female aged 18-65 years\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n\n          -  Non-metastatic, unilateral newly diagnosed primary breast cancer of clinical stage II\n             to III including inflammatory breast cancer with:\n\n               1. tumour size \u2265 2 cm\n\n               2. histologically confirmed primary invasive carcinoma of the breast\n\n               3. HER2-positivity confirmed by a central laboratory or an accredited local\n                  laboratory and defined as immunohistochemistry (IHC) 3+ or fluorescence in situ\n                  hybridisation (FISH)+\n\n          -  Known hormone receptor (oestrogen receptor and progesterone receptor) status\n\n          -  Baseline left ventricular ejection fraction (LVEF) \u2265 55% measured by echocardiography\n             or multiple gated acquisition (MUGA) scan\n\n          -  Subjects must be able to provide informed consent, which must be obtained prior to\n             any study related procedures\n\n        Exclusion Criteria:\n\n          -  Metastatic (stage IV) or bilateral or multifocal/multicentric breast cancer\n\n          -  History of any prior invasive breast carcinoma, except for subjects with a past\n             history of ductal carcinoma in situ (DCIS) and/or lobular carcinoma in situ (LCIS)\n             treated with surgery only\n\n          -  Past or current history of malignant neoplasms within 5 years prior to Randomisation,\n             except for curatively treated carcinoma in situ of uterine cervix, basal cell\n             carcinoma of the skin or squamous cell carcinoma of the skin (malignant neoplasms\n             occurring more than 5 years prior to Randomisation are permitted if curatively\n             treated with surgery only)\n\n          -  Previous history of radiation therapy, immunotherapy, chemotherapy or biotherapy\n             (including prior HER2 directed therapy) Major surgery within 4 weeks prior to\n             Randomisation and minor surgery within 2 weeks prior to Randomisation (major surgery\n             is defined as surgery which requires general anaesthesia)\n\n          -  Serious cardiac illness that would preclude the use of trastuzumab such as:\n\n               1. history of documented congestive heart failure (CHF) (New York Heart\n                  Association, NYHA, class II or greater heart disease)\n\n               2. LVEF < 55% by echocardiography or MUGA scan\n\n               3. angina pectoris requiring anti-anginal medication\n\n               4. evidence of transmural infarction on electrocardiogram (ECG)\n\n               5. uncontrolled hypertension (systolic > 180 mmHg and/or diastolic > 100 mmHg)\n\n               6. clinically significant valvular heart disease\n\n               7. high risk uncontrolled arrhythmias\n\n          -  Serious pulmonary illness enough to cause dyspnoea at rest or requiring supplementary\n             oxygen therapy\n\n          -  Known history of hepatitis B virus (HBV), hepatitis C virus (HCV) or human\n             immunodeficiency virus (HIV) infection\n\n          -  Other concurrent serious illnesses that may interfere with planned therapy including\n             severe cardiovascular, pulmonary, metabolic or infectious conditions\n\n          -  Known hypersensitivity to the investigational product (IPs), non-IPs or any of the\n             ingredients or excipients of the IPs or non-IPs\n\n          -  Known hypersensitivity to murine proteins\n\n          -  Known history of dihydropyrimidine dehydrogenase (DPD) deficiency\n\n          -  Pre-existing peripheral sensory or motor neuropathy \u2265 grade 2, defined by National\n             Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0\n\n          -  Pregnant or lactating women. A pregnancy test result is required for all women of\n             childbearing potential including women who had menopause onset within 2 years prior\n             to Randomisation. Women of childbearing potential must agree to use contraceptive\n             methods (see section 7.4.2) during the study and 6 months after the last dose of IP\n\n          -  Concurrent hormonal therapy including birth control pills, ovarian hormone\n             replacement for menopause, selective oestrogen receptor modulator (SERM) either for\n             osteoporosis or breast cancer prevention\n\n          -  Subjects unwilling to follow the study requirements"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "498", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02149524", 
            "org_study_id": "SB3-G31-BC", 
            "secondary_id": "2013-004172-35"
        }, 
        "intervention": [
            {
                "arm_group_label": "Herceptin (trastuzumab)", 
                "description": "Intravenous administration", 
                "intervention_name": "Herceptin (trastuzuamb)", 
                "intervention_type": "Drug", 
                "other_name": "Herceptin"
            }, 
            {
                "arm_group_label": "SB3 (proposed trastuzumab biosimilar)", 
                "description": "Intravenous administration", 
                "intervention_name": "SB3 (proposed trastuzumab biosimilar)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Trastuzumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HER2 Positive Breast Cancer", 
            "Trastuzumab", 
            "Biosimilar"
        ], 
        "lastchanged_date": "May 26, 2014", 
        "location": {
            "contact": {
                "last_name": "Samsung Bioepis Information Center", 
                "phone": "+82 32 455 6711"
            }, 
            "facility": {
                "address": {
                    "city": "Praha", 
                    "country": "Czech Republic"
                }, 
                "name": "Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Czech Republic"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity Between SB3 (Proposed Trastuzumab Biosimilar) and Herceptin\u00ae in Women With Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting", 
        "overall_official": {
            "affiliation": "CHU Besan\u00e7on Hopital Jean Minjoz Service d'Oncologie Medicale", 
            "last_name": "Xavier Pivot", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Bulgaria: Bulgarian Drug Agency", 
                "Czech Republic: State Institute for Drug Control", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The pathologic complete response (pCR) rate of the primary breast tumour", 
            "safety_issue": "No", 
            "time_frame": "Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02149524"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "total pathological complete response (tpCR) rate", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Overall clinical response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Event-free survival (EFS)", 
                "safety_issue": "No", 
                "time_frame": "1 month after last dose of investigational product"
            }, 
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "1 month after the last administration of investigational product"
            }
        ], 
        "source": "Samsung Bioepis Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Bioepis Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}